一分钟看懂
这是一项关于乳腺癌的II 期研究，登记的药物或干预包括SHR- A1811，当前状态为招募中。登记地点显示中国天津有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
SHR- A1811 · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Tianjin Medical University Cancer Institute and Hospital · 天津
公开的入选条件
- 1. Female subjects, aged ≥18 years and ≤75 years;
- 2. ECOG performance status 0-1;
- 3. Expected survival of no less than 3 months;
- 4. Histologically documented breast cancer:
- 1. Advanced or metastatic breast cancer
- 2. History of ultra-low HER2 expression: histopathology confirms ultra-low HER2 expression, defined as incomplete, faint membranous staining in ≤10% of invasive tumor cells.
- If multiple historical/local HER2 test results are available for a subject, the most recent result derived from metastatic or advanced disease should be adopted.
- If local HER2 testing only classifies the subject's tumor as HER2-negative without available IHC status, the result must be re-confirmed by the Department of Pathology of Tianjin Medical University Cancer Institute and Hospital.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07817082；登记信息更新于 2026-09-14。